FLASH THERAPEUTICS
Flash is developing an oral compound to prevent AML relapse using novel findings linking HCK to AML. This small molecule will inhibit HCK and FLT3-ITD for the treatment of cancer. They have identified five potential compounds for further testing. One is moving on to IND filing while the other four are going to begin animal toxicology testing.
FLASH THERAPEUTICS
Industry:
Biotechnology
Address:
Boston, Massachusetts, United States
Country:
United States
Total Employee:
11+
Status:
Active
Total Funding:
5 M USD
Similar Organizations
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Investors List
Viva Ventures Biotech Fund
Viva Ventures Biotech Fund investment in Series A - Flash Therapeutics
JMCR Partners
JMCR Partners investment in Series A - Flash Therapeutics
Viva BioInnovator
Viva BioInnovator investment in Series A - Flash Therapeutics